← Clinical Trials
Non-Small-Cell Lung Carcinoma Phase 3 Completed NCT02578680

KEYNOTE-189: Complete Statistical Analysis of Pembrolizumab in Metastatic Nonsquamous Non-Small Cell Lung Cancer

An independent statistical analysis of the randomized phase 3 KEYNOTE-189 trial evaluating pembrolizumab with pemetrexed and platinum chemotherapy versus the control regimen in participants with first-line metastatic nonsquamous non-small cell lung cancer.

Trial start: 2016-01-15  ·  Primary completion: 2017-11-08  ·  Enrollment: 616
Scope of this record

This page separates reported trial results from statistical interpretation. Numerical results are taken from the ClinicalTrials.gov record. ClinicalTrials.gov provides the official trial registry record.

Independent analysis: This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.

1. Trial at a Glance

KEYNOTE-189 was a randomized, parallel-group, quadruple-masked phase 3 treatment trial in non-small-cell lung carcinoma. The registry reports 616 participants, two arms, two registered primary endpoints, and statistical analyses for both primary endpoints plus a secondary response endpoint and a prespecified additional PFS endpoint.

616
Enrollment
2 treatment arms
2
Primary endpoints
PFS and OS
0.52
PFS HR
95% CI 0.43–0.64
0.49
OS HR
95% CI 0.38–0.64
FeatureKEYNOTE-189
Trial nameKEYNOTE-189
NCT IDNCT02578680
PhasePhase 3
StatusCompleted
Therapeutic areaOncology
ConditionNon-Small-Cell Lung Carcinoma
AllocationRandomized
Design modelParallel
MaskingQuadruple
Primary purposeTreatment
Enrollment616
Lead sponsorMerck Sharp & Dohme LLC
Sponsor typeIndustry
Primary endpoint typeTime-to-event
Results postedYes

2. Clinical Question

The registry describes KEYNOTE-189 as a study of pemetrexed plus platinum chemotherapy with or without pembrolizumab in participants with first-line metastatic nonsquamous non-small cell lung cancer. The primary statistical question was whether the pembrolizumab-containing regimen was superior to the control regimen with respect to progression-free survival and overall survival.

Population

Participants with first-line metastatic nonsquamous non-small cell lung cancer, represented in the registry under the condition Non-Small-Cell Lung Carcinoma.

Intervention

Pembrolizumab 200 mg with pemetrexed and platinum chemotherapy, with subsequent pembrolizumab plus pemetrexed in the reported comparison.

Comparator

The registry comparison is against the control regimen, described in the analysis as the control group receiving pemetrexed-platinum chemotherapy.

Primary question

Does the pembrolizumab-containing regimen improve the registered time-to-event endpoints PFS and OS compared with control?

3. Trial Design

The trial used randomized allocation, a parallel design, quadruple masking, and a treatment-oriented primary purpose. Enrollment was 616 participants across two arms.

01
Randomize616 participants
02
Two armsIntervention vs control
03
TreatmentPemetrexed + platinum framework
04
AssessPFS, OS, response
05
AnalyzeStratified survival methods
INTERVENTION

Pembrolizumab-containing regimen

  • Pembrolizumab 200 mg
  • Pemetrexed
  • Cisplatin or carboplatin
  • Folic acid 350-1000 μg
  • Vitamin B12 1000 μg
  • Dexamethasone 4 mg
  • Saline solution
CONTROL

Control regimen

  • Pemetrexed
  • Cisplatin or carboplatin
  • Saline solution and associated supportive interventions as registered

The statistical comparison reported by the registry is explicitly between pembrolizumab + pemetrexed + platinum chemotherapy followed by pembrolizumab + pemetrexed and control.

4. Primary Endpoints

Both registered primary endpoints were time-to-event outcomes with a time frame of up to approximately 21 months. The registry reports a formal statistical analysis for each endpoint.

EndpointRegistry definitionTime frameAnalysis
Progression-Free Survival (PFS) PFS was defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurred first. Per RECIST 1.1, progressive disease was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, together with an absolute increase of ≥5 mm. Up to approximately 21 months Stratified Cox regression with log-rank testing
Overall Survival (OS) OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. Up to approximately 21 months Stratified Cox regression with log-rank testing
Analysis population: For both primary endpoint analyses, the registry states that the analysis population consisted of all randomized participants.

5. Statistical Methodology

Log-rank testing for time-to-event endpoints

The registry reports the log-rank test as the primary comparison method for both PFS and OS. A log-rank test evaluates whether the event-time distributions differ between randomized groups over follow-up, accounting for the timing of events rather than reducing the endpoint to a single fixed-time proportion.

Stratified Cox regression

The reported hazard ratios were based on Cox regression with treatment as a covariate and stratification by three factors: PD-L1 status (≥1% vs. <1%), platinum chemotherapy (cisplatin vs. carboplatin), and smoking status (never vs. former/current).

Reported model structure
Treatment covariate + stratification by PD-L1 status + platinum chemotherapy + smoking status

The registry identifies pembrolizumab as the numerator and control as the denominator for the reported hazard ratios.

Score-based comparison for response

The secondary ORR analysis used the Miettinen and Nurminen method. The registry describes the analysis as treatment adjusted and stratified by PD-L1 status, platinum chemotherapy, and smoking status.

Superiority framework

All four registry-reported formal analyses are classified as superiority analyses. This is important because the interpretation is based on whether the observed treatment comparison supports a difference in favor of the intervention, rather than whether the intervention remains within a prespecified non-inferiority margin.

Analysis populations

The registry identifies all randomized participants as the analysis population for each registry-reported formal analysis. This is consistent across the two primary endpoints, the secondary ORR analysis, and the prespecified additional PFS analysis reported in the ClinicalTrials.gov record.

6. Primary Result: Progression-Free Survival

The primary PFS analysis compared pembrolizumab + pemetrexed + platinum chemotherapy followed by pembrolizumab + pemetrexed with control. The endpoint was assessed by blinded central imaging and defined according to RECIST 1.1.

Hazard ratio for progression or death

0.52

95% CI: 0.43–0.64   ·   P < 0.00001

Two-sided 95% confidence interval; superiority hypothesis.

ElementReported result
Analysis populationAll randomized participants
MethodLog-rank test; hazard ratio based on Cox regression
Effect measureHazard ratio
Estimate0.52
95% CI0.43–0.64
P-value<0.00001
HypothesisSuperiority
Clinical Biostats interpretation

An HR of 0.52 means that the fitted model estimated an instantaneous rate of progression or death approximately 48% lower in the pembrolizumab-containing group than in the control group, because 1 − 0.52 = 0.48. This is a relative time-to-event interpretation, not a statement that 48% of participants avoided progression or death.

The 95% CI of 0.43–0.64 describes uncertainty around the estimated hazard ratio under the model and analysis framework. It does not describe the range of individual patient outcomes, nor does it mean that the true treatment effect has a 95% probability of lying inside the interval.

The P < 0.00001 value addresses evidence against the null hypothesis within the specified testing framework. It does not measure the size of the treatment effect. The HR and its confidence interval describe the effect estimate and its precision; the p-value addresses statistical evidence against the null.

The analysis was stratified by PD-L1 status, platinum chemotherapy, and smoking status. Because the estimate comes from a Cox model, its interpretation also depends on the model's assumptions, including the proportional-hazards framework. The registry does not provide enough information here to independently assess that assumption from the underlying event-time data.

7. Primary Result: Overall Survival

OS was the second registered primary endpoint. It measured time from randomization to death from any cause, with participants without documented death at the interim analysis censored at their last follow-up date.

Hazard ratio for death

0.49

95% CI: 0.38–0.64   ·   P < 0.00001

Two-sided 95% confidence interval; superiority hypothesis.

ElementReported result
Analysis populationAll randomized participants
MethodLog-rank test; hazard ratio based on Cox regression
Effect measureHazard ratio
Estimate0.49
95% CI0.38–0.64
P-value<0.00001
HypothesisSuperiority
Clinical Biostats interpretation

An HR of 0.49 means that the fitted model estimated an instantaneous rate of death approximately 51% lower in the pembrolizumab-containing group than in the control group. It does not mean that 51% of participants survived, that 51% of participants were cured, or that every participant experienced the same relative reduction in mortality.

The 95% CI of 0.38–0.64 provides a measure of precision around the estimated hazard ratio. The interval is narrower than a very imprecise estimate would be, but it still reflects uncertainty arising from the finite randomized sample and observed event information.

The P < 0.00001 result is evidence against the null hypothesis under the reported superiority analysis. It is not a measure of clinical magnitude. A small p-value can occur with a modest effect when information is abundant, while a large effect estimate can be imprecise in a small study.

As with the PFS analysis, the OS estimate was obtained using a stratified Cox model. The analysis incorporated PD-L1 status, platinum chemotherapy, and smoking status as stratification factors. Censoring also matters: participants without documented death at the interim analysis contributed follow-up until their last follow-up date.

8. Secondary Endpoint Result: Overall Response Rate

Overall Response Rate (ORR) was a secondary binary endpoint defined per RECIST 1.1 as assessed by blinded central imaging. The registry reports the effect as the difference in percentage versus control.

Difference in response rate versus control

28.5 percentage points

95% CI: 21.1–35.4   ·   P < 0.0001

Two-sided 95% confidence interval; superiority hypothesis.

ElementReported result
EndpointOverall Response Rate per RECIST 1.1 as assessed by blinded central imaging
Analysis populationAll randomized participants
MethodStratified Miettinen and Nurminen
Effect measureDifference in percentage vs. control
Risk difference28.5
95% CI21.1–35.4
P-value<0.0001
Clinical Biostats interpretation

A reported difference of 28.5 percentage points means that the response-rate proportion in the pembrolizumab-containing group exceeded the corresponding control proportion by 28.5 percentage points under the reported analysis.

The 95% CI of 21.1–35.4 percentage points describes uncertainty around that between-group difference. It is a confidence interval for the difference in proportions, not an interval for an individual patient's probability of response.

The Miettinen-Nurminen method is a score-based approach for inference on differences between proportions. The analysis was stratified by PD-L1 status, platinum chemotherapy, and smoking status, so the reported estimate should not simply be interpreted as an unadjusted subtraction of two crude percentages.

The P < 0.0001 value addresses statistical evidence for a difference under the specified hypothesis test. It does not quantify how important a 28.5-percentage-point difference is clinically, and it should not be substituted for the confidence interval when discussing precision.

9. Other Prespecified Result: PFS by Investigator Immune-Related RECIST

The registry also reports a prespecified PFS analysis using investigator-assessed immune-related RECIST (irRECIST) response criteria. This endpoint was not identified as one of the two primary endpoints in the ClinicalTrials.gov record.

Hazard ratio for PFS by irRECIST

0.49

95% CI: 0.41–0.59   ·   P < 0.00001

Time frame: up to approximately 39 months.

Clinical Biostats interpretation

The HR of 0.49 corresponds to an approximately 51% lower estimated instantaneous rate of the PFS event in the pembrolizumab-containing group under this analysis. This estimate uses a different endpoint assessment framework from the primary PFS endpoint, so it should not be silently substituted for the blinded-central-imaging RECIST 1.1 result.

The 95% CI of 0.41–0.59 quantifies uncertainty around the reported hazard ratio. The very small p-value indicates strong statistical evidence against the null hypothesis under the reported test, but the p-value itself does not measure effect size or clinical importance.

10. Summary of Reported Statistical Results

EndpointRoleEffect95% CIP-value
PFS by blinded central imaging, RECIST 1.1 Primary HR 0.52 0.43–0.64 <0.00001
OS Primary HR 0.49 0.38–0.64 <0.00001
ORR by blinded central imaging, RECIST 1.1 Secondary Risk difference 28.5 percentage points 21.1–35.4 <0.0001
PFS by investigator irRECIST Other prespecified HR 0.49 0.41–0.59 <0.00001

The ClinicalTrials.gov record therefore contain formal results for both primary endpoints, one secondary endpoint, and one additional prespecified endpoint. All registry-reported formal analyses use the all-randomized analysis population.

11. Serious Adverse Events

The ClinicalTrials.gov record reports serious adverse events by arm using affected participants over participants at risk. The ClinicalTrials.gov record contains the following counts.

Reported groupAffected / at risk
Pembrolizumab + Pemetrexed + Platinum Chemot233 / 405
Control102 / 202
Control Switched Over to Pembrolizumab M29 / 84
Control Switched Over to Pembrolizumab M0 / 2
Pembrolizumab + Pemetrexed + Platinum Chemot2 / 9
Safety interpretation: These are the serious-adverse-event counts exactly as reported in the ClinicalTrials.gov record. Because the ClinicalTrials.gov record contains several separately labeled groups, including switched-over groups and repeated arm labels with different denominators, they should not be collapsed into a single pooled safety rate without the underlying registry result structure.

12. Randomization and Stratified Analysis

Randomization is the design feature that creates the principal basis for comparing the treatment groups. The registry does not supply an allocation ratio in the ClinicalTrials.gov record, so no ratio is inferred here from the enrollment total.

The formal analyses nevertheless provide important detail about stratification. Both primary time-to-event analyses used a Cox regression model with treatment as a covariate stratified by:

The ORR analysis used the Miettinen and Nurminen method with the same treatment-covariate and stratification structure. Thus, stratification was not merely a descriptive baseline feature; it was part of the inferential analysis reported by the registry.

13. Statistical Methods Explained

Why use a hazard ratio for PFS and OS?

PFS and OS are time-to-event endpoints. A hazard ratio summarizes the relative instantaneous event rate between the randomized groups over the analyzed follow-up. Unlike a fixed-time risk difference, it uses information about when events occur and accommodates censoring.

What does an HR of 0.52 mean?

An HR of 0.52 indicates that the fitted model estimated the instantaneous rate of the event at approximately 52% of the corresponding rate in the control group. Equivalently, the estimated rate was approximately 48% lower. It does not mean that 52% of patients experienced an event, nor that each patient had exactly the same relative reduction.

Why was a stratified Cox model used?

The registry states that treatment was included as a covariate while the Cox model was stratified by PD-L1 status, platinum chemotherapy, and smoking status. Stratification allows the baseline hazard to differ across those strata while estimating the treatment effect within the specified modeling framework.

Why is the log-rank test appropriate for PFS and OS?

The log-rank test is designed for comparing survival distributions between groups when observations may be right-censored. It uses the ordering of event times rather than treating every participant as if the endpoint were observed at a common fixed time.

What does the 95% CI for the hazard ratio tell us?

The 95% CI gives a range of values reflecting statistical uncertainty around the estimated hazard ratio under the model and sampling framework. For the primary PFS analysis, the interval is 0.43–0.64; for OS, it is 0.38–0.64. Neither interval describes the distribution of treatment effects across individual patients.

Why was a different method used for ORR?

ORR is a binary endpoint rather than a time-to-event endpoint. The registry reports the stratified Miettinen and Nurminen method for comparing response proportions. Its reported effect measure is a difference in percentage versus control rather than a hazard ratio.

Why does the p-value not measure effect size?

A p-value quantifies statistical evidence against a null hypothesis under the specified test. It depends on both the observed effect and the amount of information in the study. The effect estimate and confidence interval are therefore necessary to understand magnitude and precision.

14. Kaplan-Meier Estimation and Censoring

Although the registry statistical-analyses records identify log-rank testing and Cox regression, the underlying PFS and OS endpoints are time-to-event outcomes. Kaplan-Meier estimation is the standard descriptive framework for displaying the survival function for such outcomes.

Kaplan-Meier concept
S(t) = ∏ti ≤ t (1 − di/ni)

Here, di is the number of events at time ti and ni is the number at risk immediately before that time.

For OS, the registry explicitly states that participants without documented death at the time of the interim analysis were censored at the date of last follow-up. This is an important feature of survival analysis: a censored participant is not treated as having experienced the event, but their available follow-up still contributes information up to the censoring time.

The ClinicalTrials.gov record does not provide individual event times, censoring times, numbers at risk at successive time points, or a digitized survival curve. A Kaplan-Meier curve should therefore not be reconstructed from the summary hazard ratios and p-values alone.

15. Confidence Intervals and Effect Measures

KEYNOTE-189 illustrates two different classes of effect measure in the statistical analyses posted on ClinicalTrials.gov.

Hazard ratio

Used for PFS and OS. The reported estimates are 0.52 for primary PFS, 0.49 for OS, and 0.49 for the prespecified irRECIST PFS analysis.

Risk difference

Used for ORR. The reported difference in percentage versus control is 28.5 percentage points, with a two-sided 95% CI of 21.1–35.4.

These measures should not be compared as if they were on the same scale. A hazard ratio describes a relative time-to-event effect under a survival model; a risk difference describes an absolute difference between proportions.

16. Multiplicity and Hypothesis Testing

The trial data identify two registered primary endpoints, both analyzed under a superiority hypothesis. The ClinicalTrials.gov record does not provide an alpha-spending plan, interim-analysis boundary, formal multiplicity allocation scheme, or detailed hierarchical testing sequence.

FeatureWhat the ClinicalTrials.gov record supportsWhat is not reported
Primary endpoints2: PFS and OSDetailed alpha allocation between them
Hypothesis typeSuperiorityDetailed testing hierarchy
Primary p-valuesPFS <0.00001; OS <0.00001Multiplicity-adjusted alpha values
Interim analysisThe OS definition references an interim analysisBoundary, alpha spending, or information fraction
Additional analysisirRECIST PFS reported as Other_Pre_SpecifiedFormal multiplicity relationship to primary endpoints
Interpretation boundary: The very small reported p-values should be interpreted according to the registry's stated analysis framework. The ClinicalTrials.gov record does not provide enough information to reconstruct a complete familywise-error strategy, so no additional alpha-spending or multiplicity procedure is attributed to the trial here.

17. Missing Data and Imputation

The ClinicalTrials.gov record does not report a missing-data or imputation method for the primary endpoints. For OS, the registry explicitly describes censoring for participants without documented death at the interim analysis. For PFS, the endpoint is likewise a time-to-event measure, but the registry text does not provide a separate imputation algorithm.

This distinction matters statistically. Censoring is not the same as imputation. In a survival analysis, a participant whose event has not been observed by the last available follow-up is typically treated as right-censored rather than assigned an invented event time.

18. Blinding and Outcome Assessment

the ClinicalTrials.gov record identifies the study as quadruple-masked. The primary PFS endpoint was assessed by blinded central imaging, and the secondary ORR endpoint was also assessed by blinded central imaging.

Blinding

Quadruple masking reduces opportunities for knowledge of treatment assignment to influence trial conduct and assessment.

Central imaging

Blinded central imaging provides a standardized assessment framework for RECIST 1.1-based PFS and ORR endpoints.

For the additional prespecified PFS analysis, the registry identifies investigator-assessed immune-related RECIST criteria rather than blinded central imaging. That difference in assessment framework is an important reason to keep the endpoint analyses distinct.

19. Non-Inferiority, Bayesian Methods, and Other Design Topics

The ClinicalTrials.gov record classifies the formal hypotheses as superiority. No non-inferiority margin is reported, so there is no non-inferiority margin to interpret for this trial.

No Bayesian method is identified in the registry-reported statistical methodology. The normalized methods are the log-rank test and score-based confidence intervals for proportions using the Miettinen-Nurminen, Newcombe, or Wilson family of methods.

The ClinicalTrials.gov record also do not report a factorial design. The design model is parallel with two arms.

20. What the Hazard Ratios Do — and Do Not — Mean

PFS HR 0.52

The primary PFS HR of 0.52 represents an estimated 48% lower instantaneous rate of progression or death under the reported Cox model. It does not mean a 48% absolute improvement in PFS, and it does not imply that 48% of participants benefit.

OS HR 0.49

The OS HR of 0.49 represents an estimated 51% lower instantaneous rate of death under the reported model. It is a relative time-to-event measure and should not be translated directly into an absolute survival percentage.

Why the confidence intervals matter

The PFS CI of 0.43–0.64 and OS CI of 0.38–0.64 communicate the precision of the respective estimates. They provide more information than the p-values alone because they show the range of effect estimates compatible with the statistical uncertainty represented by the analysis.

21. Important Limitations and Interpretation Issues

22. Why This Trial Matters Statistically

KEYNOTE-189 provides a compact teaching example of how randomized clinical-trial evidence can combine time-to-event and binary endpoints while accounting for prespecified stratification factors.

ConceptHow it appears in KEYNOTE-189
RandomizationRandomized parallel-group phase 3 design with 616 participants
BlindingQuadruple masking
Time-to-event endpointsPFS and OS
RECIST 1.1Primary PFS and secondary ORR assessed by blinded central imaging
Log-rank testReported formal method for both primary endpoints
Hazard ratioEffect measure for PFS and OS
Cox regressionUsed with treatment as a covariate and prespecified stratification factors
Stratified analysisPD-L1 status, platinum chemotherapy, and smoking status
Risk differenceEffect measure for ORR
Miettinen-Nurminen methodReported method for the secondary ORR comparison
Confidence intervals95% two-sided intervals for all registry-reported formal effect estimates
Superiority testingHypothesis type for all registry-reported formal analyses
CensoringExplicitly described for participants without documented death at the OS interim analysis

23. Statistical Methods Explained: Practical Interpretation

Relative vs absolute effects

The HRs describe relative event rates, whereas the ORR risk difference describes an absolute difference in response proportions. These should not be treated as interchangeable measures.

Precision vs significance

The confidence interval addresses precision. The p-value addresses evidence against the null hypothesis. Neither quantity alone provides a complete description of the treatment effect.

Stratification vs subgroup analysis

A factor can be used for stratification without being the subject of a treatment-effect heterogeneity claim. The ClinicalTrials.gov record identifies PD-L1 status, platinum choice, and smoking status as stratification factors.

Assessment framework

Primary PFS and ORR used blinded central imaging under RECIST 1.1, while the additional PFS analysis used investigator-assessed immune-related RECIST criteria.

24. Related Tutorials

Learn more about the statistical methods used in this trial:

25. Related Calculators

26. Sources

Continue with the statistical methods

Explore the survival-analysis, confidence-interval, and clinical-trial methods that appear in KEYNOTE-189.

27. Record Summary

KEYNOTE-189 illustrates a randomized phase 3 statistical framework combining two primary time-to-event endpoints with a secondary binary response endpoint. The primary PFS analysis reported an HR of 0.52 (95% CI 0.43–0.64; P < 0.00001), while the primary OS analysis reported an HR of 0.49 (95% CI 0.38–0.64; P < 0.00001). The secondary ORR analysis reported a risk difference of 28.5 percentage points (95% CI 21.1–35.4; P < 0.0001). A further prespecified irRECIST PFS analysis reported an HR of 0.49 (95% CI 0.41–0.59; P < 0.00001).

The statistical interpretation depends on understanding what each effect measure represents. Hazard ratios summarize relative time-to-event effects under a Cox model, while the ORR risk difference describes an absolute difference between binary response proportions. The trial also demonstrates the importance of prespecified stratification, blinded central assessment, censoring, confidence intervals, and the distinction between primary and additional endpoint analyses.

Clinical Biostats methodology: A trial-results page should distinguish reported evidence from statistical interpretation. For KEYNOTE-189, the ClinicalTrials.gov record supports formal conclusions about the reported effect estimates and their uncertainty, but they do not support reconstruction of unpublished baseline tables, subgroup estimates, detailed multiplicity procedures, missing-data algorithms, or individual-level survival curves.